Vertex verges on big time
But hepatitis drug faces competition and some investors wary of stock
Earlier this year, Joshua Boger , chief executive of Vertex Pharmaceuticals Inc. , stood before several hundred scouts from the country's top mutual funds and drug companies and delivered a piece of news that could make his 17-year-old Cambridge biotech firm profitable for the first time. (Full article: 1440 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
